Skip To Content
Digital Health


Fully integrated healthcare platform offering a safe space for men to address their health concerns

  • Sokratis Papafloratos, CEO
  • London, UK
Visit Website
  • September 2021
  • Current
  • Series B

The Investment

Men have historically not engaged with their health in the way that they should, and the effects of this are staggering.

Driven by underlying social stigmas that have shaped the self-perception of men for generations, men have an innate fear of addressing health concerns due to the associated shame as well as a lack of convenience that often comes in doing this. As a result, men are reportedly far more likely to suffer from cancers, heart disease, obesity and poor mental health.

Sokratis founded Numan in 2018, a fully integrated healthcare platform, to provide a safe space for men to address their health concerns. Supported by a powerful e-health platform, Numan facilitates various links across these healthcare products and services to provide a holistic end-to-end experience to help close the health engagement gap for men.

Why We Invested

Partnering with Numan to Close the Men’s Health Engagement Gap

Eric Martineau-FortinNicholas StocksBlanche Ajarrista

We are pleased to announce that we have led Numan's $40m Series B round, alongside Novator, VNV Global, Anthemis and Colle Capital. This is just the start for Numan, and we could not be more excited to support Sokratis and the fantastic team that he has put together to realise their new vision for healthcare.

Read the post

In the News

Numan raises $20M debt funding from Kreos Capital, completing its $60.1M Series B

Numan, the leading digital platform for men’s health in Europe, has raised $20M in growth debt to fuel its expansion and meet the growing demand for digital health services in the UK and beyond. The financing was provided by growth debt investor, Kreos Capital. It completes a $60.1M Series B round, which was led by White Star Capital, with participation from Novator, VNV Global, and Anthemis Exponential.

Want to learn more about our investments?

Back to All Companies

Subscribe to
our newsletter

We don't support Internet Explorer

Please use Chrome, Safari, Firefox, or Edge to view this site.